ETV6 Rearrangement Suppresses CDKN1B Transcription by Disrupting an Intragenic Super-enhancer in Acute Lymphoblastic Leukemia.

Disruption of an intragenic super-enhancer by ETV6 rearrangements downregulates CDKN1B, activating NF-κB and promoting treatment resistance in ALL.

• Why it matters: Understanding how ETV6 rearrangements influence gene regulation is crucial because ETV6-rearranged ALL is linked to poor prognosis and treatment resistance, yet the underlying mechanisms remain unclear.
• What they did: The study used CRISPR interference and knockout techniques to identify the core enhancer within ETV6-SE that regulates CDKN1B, and examined chromatin interactions and gene expression in patient-derived xenograft models.
• The result: Disruption of ETV6-SE impairs CDKN1B expression, activates NF-κB signaling, and increases anti-apoptotic BCL-2/BCL-XL levels, suggesting potential therapeutic benefits of combining BCL-2/BCL-XL inhibitors with dexamethasone.